Pliant Therapeutics to Participate in Upcoming Investor Conferences
August 30 2023 - 8:00AM
Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage
biotechnology company focused on discovering and developing novel
therapeutics for the treatment of fibrosis, today announced
participation in the following September investor conferences.
- Citi 18th Annual BioPharma
Conference Members of senior management will meet with
investors on Wednesday, September 6, 2023.
- H.C. Wainwright 25th Annual
Global Investment Conference Bernard Coulie, M.D., Ph.D.,
Pliant’s President and Chief Executive Officer will provide a
company update on Tuesday, September 12, 2023, at 2:00 pm Eastern
Time.
- Baird 2023 Global Healthcare
Conference Dr. Coulie will participate in a fireside chat
on Wednesday, September 13, 2023. This is an invitation-only event
hosted by Baird.
- Cantor Global Healthcare
Conference Dr. Coulie and Éric Lefebvre, M.D., Pliant’s
Chief Medical Officer, will participate in a fireside chat on
Thursday, September 28, 2023 at 11:30 am Eastern Time.
Interested parties may access the live webcasts of the H.C.
Wainwright presentation and the Cantor fireside chat by visiting
the Investor Relations’ Events & Presentation page of Pliant’s
website. The webcast replays will be archived on the Pliant website
for 30 days following the conclusion of the events.
About Pliant Therapeutics, Inc.Pliant
Therapeutics is a clinical stage biopharmaceutical company focused
on discovering and developing novel therapies for the treatment of
fibrosis. Pliant's lead product candidate, bexotegrast (PLN-74809),
is an oral, small molecule, dual selective inhibitor of αvß6 and
αvß1 integrins that is in development in the lead indications for
the treatment of idiopathic pulmonary fibrosis, or IPF, and primary
sclerosing cholangitis, or PSC. Bexotegrast has received Fast Track
Designation and Orphan Drug Designation from the U.S. Food and Drug
Administration (FDA) in IPF and PSC and Orphan Drug Designation
from the European Medicines Agency in IPF and PSC. Pliant has
initiated BEACON-IPF, a Phase 2b trial of bexotegrast in IPF.
Pliant has also developed PLN-1474, a small molecule, selective
inhibitor of αvß1 integrin for the treatment of nonalcoholic
steatohepatitis, or NASH with liver fibrosis. Pliant has initiated
a Phase 1 study for its third clinical program, PLN-101095, a small
molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that
is being developed for the treatment of solid tumors. In addition
to clinical stage programs, Pliant currently has a preclinical
program targeting muscular dystrophies. For additional information,
please visit: www.PliantRx.com. Follow us on social media
Twitter, LinkedIn, Facebook and YouTube.
Investor and Media Contact:
Christopher KeenanVice President, Investor Relations and
Corporate CommunicationsPliant Therapeutics,
Inc.ir@pliantrx.com
Pliant Therapeutics (NASDAQ:PLRX)
Historical Stock Chart
From Apr 2024 to May 2024
Pliant Therapeutics (NASDAQ:PLRX)
Historical Stock Chart
From May 2023 to May 2024